Feb 4 (Reuters) - Biotech firm PrimeGen US will go public in the United States through a $1.5 billion deal with blank-check ...

Stem cell therapy biotech PrimeGen US is taking the less-traveled special purpose acquisition company (SPAC) route to the ...

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

A major biotech company has announced plans to lay off more than 100 positions from its Franklin, Massachusetts, facility. According to a Workers Adjustment and Retraining Notification notice, layoffs ...

A surge in Inventiva shares, up about 50% in the first few weeks of 2026, highlights investors' appetite for ​betting on the ...

A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual ...

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

The business may not be as strong as its performance this year suggests.

Feb 4 (Reuters) - Biotech firm Bio-Techne beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug development. The ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.